Product Description: Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
Applications: Cancer-Kinase/protease
Formula: C21H22F2N6O2
Citations: bioRxiv. 04 Nov 2021./bioRxiv. 2024 Feb 1./BMC Cancer. 2024 Dec 5;24(1):1502./Cell Rep Med. 2023 Jan 10;100911./Eur J Med Chem. 2020 Aug 30;207:112744./J Anal Sci Technol. 2020 Jun./Life. 2025 Jan 15;15(1):99./Mol Cancer Ther. 2021 Oct 8;molcanther.MCT-21-0632-A.2021./Mol Oncol. 2022 Oct 1./Ruprecht Karls University. The Faculty of Bio Sciences. 2023 Feb 2./Spectrochim Acta A Mol Biomol Spectrosc. 2023 Nov 5, 300, 122914./Nat Nanotechnol. 2025 Feb;20(2):311-324.
References: [1]Karyn Bouhana, et al. LOXO-101, a pan TRK inhibitor, For The Treatment Of TRK-driven Cancers./[2]Nagasubramanian R, et al. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70./[3]Kathryn G, et al. Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood 2016 128:278./[4]Doebele RC, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049-57.
CAS Number: 1223403-58-4
Molecular Weight: 428.44
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : ≥ 4.6 mg/mL
Target: Apoptosis;Trk Receptor
Deutsch
English
